65 results about "Dry powder inhalation" patented technology

The invention provides a medication monitoring device and a medication monitoring method, relates to the field of medical apparatuses and instruments, and solves the technical problem that whether a capsule rotates to release medicines or not is difficult to monitor in a capsule type dry powder inhalation used in a transversely placed inhaler. The medication monitoring device comprises a shell and a photoelectric sensor, the photoelectric sensor is arranged on the shell, and a light path of the photoelectric sensor is configured to penetrate through the air inlet of the inhaler and the medicine bin, so that the rotation state of the capsule in the medicine bin is judged by detecting the change of the light path; the photoelectric sensor and the air inlet of the inhaler are arranged in a spaced mode in space so as to allow the inlet air flow to pass through. The rotation state of the capsule in the medicine bin is judged by detecting the change of the light path, whether the capsule rotates or not can be directly monitored, the problems that in the prior art, whether the capsule rotates or not cannot be known, and medicine taking failure caused by improper posture of the capsule cannot be judged are solved, effectiveness of medicine taking monitoring is ensured, and medicine taking guidance is facilitated.

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

The invention relates to the technical field of powder inhalation inhalers, in particular to a monitoring device for a capsule type powder inhalation inhaler. The monitoring device comprises a shell, the inhaler is installed on the shell, the shell is provided with a photoelectric sensor, the photoelectric sensor comprises an emitter and a receiver, the emitter and the receiver are arranged at the positions of two air inlets of the inhaler respectively, a set distance is reserved between the emitter and the air inlets, and a set distance is reserved between the receiver and the air inlets. The centers of the emitter, the receiver, the air inlet and the inhaler are positioned on the same straight line; the distance between the emitter and the air inlet and the distance between the receiver and the air inlet range from 0.99 mm to 8 mm. According to the invention, the airflow velocity can be indirectly obtained by directly monitoring the rotation state of the capsule, and meanwhile, the interference to normal air intake of the inhaler is reduced, so that the reliability and effectiveness of medication monitoring are improved.

The present invention relates to an ambroxol-ibuprofen cocrystal dry powder inhaler, a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhaler is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1:1, and the mass ratio of lactose to ambroxol-ibuprofen cocrystal is 5-35%. The results of the rat lung tissue distribution experiment showed that the administration method of dry powder inhalation can significantly enhance the drug delivery efficiency in the lungs and greatly prolong the drug retention time in the lungs compared with the traditional intravenous administration. Pharmacodynamic experiments further revealed that the ambroxol-ibuprofen cocrystal dry powder inhaler can effectively inhibit the active expression of inflammatory factors in model animals, and reduce the accumulation of hydroxyproline (HYP) in lung tissue and serum, improve anti-fibrosis and anti-inflammatory capabilities, improve oxidative stress capabilities, thereby helping to delay the pathological process of pulmonary fibrosis, showing great development potential as an anti-pulmonary fibrosis drug.

The present invention belongs to the technical field of medical devices, and particularly relates to a dry powder inhalation device with a rotating multi-capsule channel that is sequentially opened for inhalation, which is mainly used for administering in the form of a dry powder inhalant, and includes: a mouthpiece; a housing, a chamber is formed inside the housing; a plurality of capsule compartments are formed in the chamber and can be communicated with the mouthpiece; a diversion part is movably arranged between the mouthpiece and the plurality of capsule compartments to communicate the mouthpiece with one capsule compartment; a driving part is connected to the housing and the diversion assembly, and the driving part can rotate relative to the housing to drive the diversion assembly to move between the mouthpiece and the plurality of capsule compartments, so that different capsule compartments are communicated with the mouthpiece, solving the problem that: in the existing multi-capsule powder inhaler, when the user inhales the drug through the mouthpiece, the mouthpiece is communicated with each capsule compartment, resulting in the user's suction being dispersed into each capsule compartment, making it difficult for the user to inhale the drug, and thus reducing the inhalation efficiency.

The present invention relates to carrier particles for dry powder formulations for inhalation and a process for preparing the same.

A pharmaceutical composition for dry powder inhalation is provided, including an active ingredient and a pharmacologically acceptable excipient. The active ingredient includes an active compound with a molecular weight of less than 1000 Daltons. The pharmacologically acceptable excipient includes amino acid, sugar, sugar alcohol, polyol, phospholipid, or a combination thereof, or a combination thereof, in which a weight ratio of the pharmacologically acceptable excipient and the active ingredient is from 1:1 to 99:1. In some embodiments of the present disclosure, a method of preparing a pharmaceutical composition for dry powder inhalation is further provided. By regulating the amount of the pharmacologically acceptable excipient, the aerosol property of the pharmaceutical composition can be predominantly influenced by the pharmacologically acceptable excipient, thereby reducing the impact of the active ingredient on the aerosol property and expanding the range of the active ingredient applicable to the pharmaceutical composition.

A dry powder inhalation system includes a breath detection device, a drug delivery device, and a computing device. The breath detection device is configured to monitor the breathing state of an animal and transmit the signals of the breathing state. The drug delivery device is configured to deliver the dry powder orally or nasally to the lungs of the animal. The computing device is configured to receive the signals of the breathing state, evaluate a stress state of the animal, predict a breathing cycle of the animal, and control the drug delivery device to release the dry powder during a non-stressed inhalation period for the animal to inhale the dry powder autonomously. A dry powder administration method is also disclosed.

This invention relates to the field of filling equipment technology and discloses a storage-type automated filling equipment for dry powder inhalers. The equipment includes a workbench, a frame fixedly mounted on the top of the workbench, a mounting frame mounted on the top of the frame, a support frame fixedly mounted on the top of the mounting frame, and a drive motor mounted on the top of the support frame. The output shaft of the drive motor passes through the interior of the mounting frame and is fitted with a track. A rotating rod is rotatably mounted inside the mounting frame, and the bottom of the rotating rod passes through the interior of the mounting frame and is fixedly fitted with a rotating wheel. In this invention, a camera, a rotating wheel, a positioning wheel, a drive motor, and an electric push rod work together. The electric push rod pushes the positioning wheel to clamp the filling bottle, the drive motor drives the rotating wheel to rotate and adjust the bottle angle, and the camera identifies and positions the bottle in real time, accurately correcting the bottle placement to ensure precise alignment between the filling nozzle and the discharge port of the filling component.

The invention relates to the technical field of nasal preparation administration devices, in particular to a nasal dry powder inhalation administration device for children, which comprises a shell, an extrusion sealing mechanism, an auxiliary administration mechanism and a dose dividing mechanism. Wherein the dose dividing mechanism can realize accurate dose dividing and quantitative control of medicine powder according to physiological characteristics and medication requirements of children of different age groups; the auxiliary drug delivery mechanism is connected to the drug outlet end of the drug delivery pipe, the drug delivery path can be optimized according to the structural characteristics of the nasal cavity of a child, drugs are effectively guided to be deposited in the absorption area of the nasal cavity, and waste of the drugs in non-absorption areas such as the nasal vestibule is reduced; the extrusion sealing mechanism can stably spray out medicine powder in the shell through the medicine feeding pipe, and the medicine powder cooperates with the auxiliary medicine feeding mechanism, so that the delivery efficiency of the medicine in the nasal cavity is improved.

The present invention relates to pharmaceutical dry powder formulations, comprising (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) of formula (I-M-II) in combination with a lactose carrier, comprising lactose monohydrate as a mixture of coarse lactose and fine lactose, and to the process of manufacturing such pharmaceutical dry powder formulations and its application for use in the treatment of cardiopulmonary disorders, such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP).

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

The invention discloses a carrier-free mometasone furoate dry powder inhaler and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the carrier-free mometasone furoate dry powder inhaler comprises mometasone furoate and an excipient, and the preparation method comprises the following steps: firstly, mixing mometasone furoate and the excipient according to a mass ratio of 10: 90-90: 10, transferring into a beaker, adding a proper amount of water, stirring, and carrying out suction filtration; adding an ethanol-water mixed solution, and stirring until solids are completely dissolved to obtain a spray-dried raw material solution; carrying out spray drying on the spray drying raw material solution by adopting a spray dryer, and collecting a product after drying to obtain microspheres, namely the carrier-free mometasone furoate dry powder inhalant. According to the carrier-free mometasone furoate dry powder inhalant, lactose does not need to be used as a carrier, the allergy risk possibly caused by lactose is avoided, meanwhile, a microsphere structure with the surface wrinkled is formed through a spray drying technology, the medicine mainly exists in an amorphous state, and the dispersity and solubility of mometasone furoate are remarkably improved.

The present invention relates to a dry powder composition for an inhalation formulation comprising formoterol or a pharmaceutically acceptable salt thereof, a tiotropium bromide anhydride and a pharmaceutically acceptable carrier. The synthesis methods of the formoterol and the tiotropium bromide are respectively realized through specific chemical reaction steps, and finally high-purity active ingredients are obtained. The weight ratio of the active ingredients to the carrier in the composition is 1: (1-15): (50-50000), and the carrier can be selected from lactose, cane sugar, mannitol or amino acid and the like. The preparation method comprises the following steps: micronizing, mixing, filling into hollow capsules, and finally preparing a finished product through aluminum-plastic packaging. The composition disclosed by the invention has good chemical stability and high inhalation efficiency, can be kept for more than two years at normal temperature, and is accurately and uniformly administered in a targeted lung through a dry powder inhalation device, so that formoterol and tiotropium bromide synergistically play a role in relaxing bronchial smooth muscles, and clinical requirements are met.

To provide a system for delivering clofazimine to the lungs of a patient.SOLUTION: A system for use in providing antibiotic activity is provided including a dry powder inhalation device and a pharmaceutical composition. The pharmaceutical composition comprises clofazimine, or a pharmaceutically acceptable salt or derivative thereof, of one or more appropriate particle size, and a physiologically acceptable pharmacologically inert excipient, or a mixture of physiologically acceptable pharmacologically inert excipients of appropriate particle size or sizes. The clofazimine is provided in the form of finely divided particles having an aerodynamic mass median diameter of less than 5 μm.SELECTED DRAWING: None

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

The invention relates to a single-dose type dry powder administration device, and belongs to the field of dry powder inhalers. Comprising a device body and a medicine bin assembly. Wherein the medicine bin assembly comprises a medicine bin main body, a medicine bin cover, a sealing film and a gasket, the medicine bin main body is used for storing medicine powder, an empty groove is formed in the medicine bin cover, the sealing film is packaged and fixed on the medicine bin cover, and the medicine bin main body and the medicine bin cover are fixed through a buckle; the gasket is arranged between the medicine bin body and the medicine bin cover. By means of the structure, the packaging piece and the medicine powder are separated, the situation that in the packaging process, due to the temperature, the biomacromolecule medicine powder loses activity is avoided, and medicine with the strict requirement for the storage temperature can be treated through a dry powder inhalation means.

A dry drug powder inhalation device comprises a breath detection device, a drug delivery device and a computer device. The respiration detection device is configured to monitor a respiration state of an animal and transmit a plurality of respiration state signals. The administration device is configured to orally or nasally apply a dry drug powder to the lungs of the animal. The computer device is configured to receive the breathing status signal, assess a tense status of the animal, predict a breathing cycle of the animal, and control the administration device to release dry drug powder for autonomous inhalation by the animal during non-tense inspiration. Also disclosed herein are methods of drug dry powder administration. The medicine dry powder inhalation device can improve effective administration of medicine dry powder to bronchus or lungs through the trachea of an animal.

The present invention provides: a nicotine dry powder inhalation composition; and a method for producing same. The nicotine dry powder inhalation composition comprises nicotine powder and flavor powder, the composition being characterized in that: the nicotine powder includes a nicotine or nicotine salt, an amino acid, and an excipient; the flavor powder includes a flavor and an excipient; and the nicotine content is less than 0.5 wt% with respect to the total dry powder composition.

The invention discloses a cationic immune liposome dry powder inhaler as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cationic immune liposome dry powder inhaler disclosed by the invention is prepared from siRNA (small interfering Ribonucleic Acid) used for KRAS mutation, (2, 3-dioleyloxypropyl)-trimethyl ammonium chloride, dipalmitic acid phosphatidylcholine, cholesterol, 1, 2-distearoyl-SN-glycerol-3-phosphorylethanolamine-N-maleimide-polyethylene glycol 2000, palbolizumab and a freeze-drying protective agent. The composition is prepared through a freeze-drying process. The preparation method of the dry powder inhaler comprises the following steps: preparing the cationic liposome carrying the siRNA, preparing the cationic immune liposome coupled with the antibody, and freeze-drying the dry powder inhaler. Compared with a traditional administration mode, the inhalant has the advantages of being simple in preparation process, good in drug stability, high in targeting performance, obvious in-vivo distribution advantage and the like, and a new strategy is provided for treatment of the non-small cell lung cancer.

The invention provides a dry powder inhalation preparation taking enoxone as an active ingredient. The preparation is small in particle size, high in lung delivery efficiency, small in dosage and capable of remarkably improving the medication compliance of patients. The dry powder inhalation preparation can significantly reduce the level of white blood cells in pulmonary alveolar lavage fluid of a bronchial asthma rat model, improve the lung function and the lesion degree of trachea, bronchus and lung, and has an obvious treatment effect on bronchial asthma.

The application discloses a preparation method of inhalation budesonide superfine crystal with adjustable particle size; the preparation method comprises the following steps: (1) dispersing and dropping budesonide solution A into a deep cold environment with a temperature of-100 to-200 DEG C, and rapidly solidifying the liquid drops into spherical composite particles; (2) under the action of stirring, adding the solidified spherical composite particles in the step (1) into an aqueous solution containing an emulsifier with a temperature of-5 DEG C to 15 DEG C, and obtaining budesonide superfine crystal. The particle size of the budesonide superfine crystal can be effectively adjusted by changing the concentration of the solution A; the obtained superfine crystal product is an ellipsoid with uniform particle size, a roundness value of 0.6 to 1.0, a CV value of 20% to 30%, an average particle size range of 1 to 10 microns, and a unique crystal form; the product is suitable for being developed into an inhalation administration dosage form, especially a dry powder inhalation agent; the process is stable, does not need a post-granulation process such as airflow crushing, is energy-saving and environment-friendly, and can realize large-scale preparation and production.

To provide a dry powder inhalation treatment for pulmonary arterial hypertension, a method of treating a patient suffering from pulmonary arterial hypertension, a dry powder inhalation composition for treatment, and a method of producing particles for delivering a dry powder to the lungs of a patient with pulmonary arterial hypertension.SOLUTION: The dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising more than 25 micrograms of treprostinil enclosed in a capsule. The dry particles may include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent, and a buffer. A method of treating a patient suffering from pulmonary arterial hypertension comprises the steps of providing the patient with a dry powder inhaler, and providing the patient with at least one capsule for use in the dry powder inhaler, the capsule containing at least 25 micrograms of treprostinil.SELECTED DRAWING: Figure 1

1. The name of the design product: dry powder inhaler. 2. The use of the design product: the design product is used to assist dry powder inhalation of medicine. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a drug product or a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

The invention discloses a rifapentine capsule type dry powder inhaler and a preparation method thereof, the capsule type dry powder inhaler comprises a capsule shell and a capsule content, and the capsule content comprises the following components in parts by weight: 1 part of rifapentine, 1-30 parts of a carrier and 0.01-1 part of a flow aid. According to the invention, micronized drug bulk drugs and appropriate excipients are in the form of capsules, and atomized drugs are actively inhaled into the lungs by a patient through a specially-made dry powder inhalation device. The delivery efficiency of the preparation is high, and the lung deposition rate is high; the particle size of the preparation and the stability of the preparation are high, and the compatibility between raw materials and auxiliary materials is good. The rifapentine capsule type dry powder inhaler disclosed by the invention has no gastrointestinal tract degradation effect and no liver first-pass effect, the medicine can directly act on the lung, the absorption is quick, and the effect is quick after administration; meanwhile, local administration is realized, the dosage is obviously reduced, and toxic and side effects are small. The preparation method disclosed by the invention is simple and easy to implement, has no too high requirements on technical equipment, and is suitable for domestic industrial production.

The invention provides a dry powder composition for relaxing an airway, a dry powder inhalation preparation and a preparation method thereof, and relates to the technical field of medicines, the dry powder composition comprises a carrier and a micronized drug active ingredient dispersed in the carrier, and the mass ratio of the micronized drug active ingredient to the carrier is 1: (11-21); the carrier comprises a coarse powder carrier and a micronized fine powder carrier; the pharmaceutical active component is composed of JKN2304 and glucocorticoid, a JKN2304-glucocorticoid duplex dry powder composition with inhaled glucocorticoid (ICS) and a beta2 receptor agonist effect and a cholinergic M receptor antagonist effect is constructed, the effects of relaxing the airway and inhibiting inflammation are achieved at the same time, the problem that a single powder inhalation is single in effect is solved, and the pharmaceutical composition is suitable for clinical application. The possibility of drug interaction is reduced. The dosage of fine particles is increased; the coarse powder carrier improves the fluidity and the total delivery amount, and a dispersion-delivery synergistic mechanism is formed.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.